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7.3 HePAtitis b DiseAse (r Kamenwa)
INTR0DUCTI0N 
Approximately 350 – 400 million people worldwide are chronically infected with the hepatitis b 
virus (Hbv), and approximately 1 million die annually of Hbv-related disease. The worldwide 
prevalence of hepatitis b virus ranges from 0.1% to 20%). This wide range is largely due to dif-
ferences in age at the time of infection. following acute Hbv infection, the risk of developing 
chronic infection varies inversely with age: 90% for perinatal infection, 25–35% for infection 
at age 1–5 years and less than 10% for adults. About 45% of the world population live in areas 
where chronic Hbv is highly endemic (≥8% of the population are hepatitis b surface antigen 
(HbsAg) positive), 43% live in intermediate-endemicity areas (2–7% HbsAg-positive) and 12% 
live in low-endemicity areas (0.6% to <2% HbsAg-positive). in the WHo European region 
the HbsAg sero-prevalence ranges from 0.3% to 12% with up to 3.5 million carriers. central 
Asian republics and parts of Eastern Europe are high endemic areas. intermediately endemic areas 
include eastern and southern Europe and the russian federation, while northern and Western 
Europe are low endemic areas. 
More than 2 000 million people alive today have been infected with Hbv at some time in their 
lives. Three quarters of the world’s population live in areas where there are high levels of infection. 
Every year there are over 4 million acute clinical cases of Hbv, and about 25% of carriers, 1 mil-
lion people a year, die from chronic active hepatitis, cirrhosis or primary liver cancer.
in developing countries the majority of Hepatitis b virus (Hbv) infection is acquired in early 
infancy or childhood. The acute infection often goes unrecognized and most of the morbidity and 
mortality from this disease occurs many years later. This has resulted in failure of appreciation of 
the full impact of this disease. 
currently, effective, affordable treatment for Hepatitis b disease is not available. immunization is 
the mainstay for prevention and control of the disease. 
Structure of HBV 
Hbv is a double stranded DNA virus belonging to a unique virus group referred to as HEPAD-
nA. Electron microscopically, the whole virus (DAnE PArticLE) is 42nm in diameter. 
The virus consists of a central core and an outer coat, both of which are antigenically represented 
as Hepatitis b core antigen (HbcAg) and Hepatitis b surface antigen (HbsAg) respectively. 
Hepatitis B Markers 
The following hepatitis b markers have been identified:
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• HbsAg was the first Hbv marker identified and was named Australian antigen by brumberg 
in 1967. The presence of HbsAg in blood is an indication of acute or chronic infection. 
Persistence of HbsAg beyond six months in the blood indicates chronic hepatitis b carriage. 
When it disappaers, the antibodies against hepatitis b (anti-Hbs) are formed. This indicates 
immunity to hepatitis b. 
• HbcAg is deeply seated in the nucleus and is not found in the blood. it can be detected in 
liver tissues after liver biopsy. However its antibody, the anti- Hb 
• core anti body (anti-Hbc) is found in blood. The antigen (HbcAg) andthe antibody(an-
ti-Hbc) appear concurrently at the time of infection. The presence of the antibody (anti-Hbc) 
indicates acute or chronic infection which can be differentiated by doing igM or igG an-
ti-Hbc. igM anti-Hbc indicates acute infection within one year and igG indicates chronic or 
past infection. 
• HbeAg is found in the blood and its presence indicates viral replication and therefore high 
infectivity of the patient. Anti-Hepatitis be antibody (anti-Hbe) appears in the blood once 
the antigen disappears and indicates reduced infectivity. 
• DnA polymerase is an enzyme found in the blood during infection and indicates active rep-
lication of the virus. 
• Hbv-DnA is the most sensitive index of viral replication or infectivity.
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The table below provides a summary of the markers.
serological Markers of Hepatitis b virus*
Term Abbreviation Comments
Hepatitis b virus
Hepatitis b surface antigen
Hepatitis b e antigen
Hepatitis b core antigen
Antibody to HbsAg
Antibody to HbeAg
Antibody to HbcAg
igM class antibody
Hbv
HbsAg
HbeAg
HbcAg
Anti-Hbs
Anti-Hbe
Anti-Hbc
igM anti-Hbc
Aetiologic agent of ‘serum’ hepatitis: also 
known as ‘Dane particle’
surface antigens of Hbv, detectable in 
large quantity in serum; several subtypes 
identifiable
Associated with Hbv replication, high ti-
tre Hbv in serum and infectivity of serum
function uncertain, no commercial test 
available and so cannot be detected in cir-
culating blood
indicates infection with and immunity to 
Hbv, passive antibody from HbiG, or 
immune response from Hb vaccine
Presence in serum of HbsAg carrier indi-
cates lower titre of Hbv
indicates prior infection especially igG 
with Hbv at some undefined time
indicates recent infection with Hbv, and 
acute viral hepatiis, detectable for 4 to 6 
months after infection.
such patients are highly infectious
* Adapted from ‘Protection Against viral Hepatitis – recommendations of the immunization 
Practices Advisory committee (AciP), from Morbidity and Mortality Weekly report 39 (rr2): 
1-26, 2/9/90
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epidemiology 
Transmission and Risk Factors
Hbv is detected in blood and body fluids (semen, saliva, nasopharyngeal fluids), and there are 
four major modes of transmission:
• sexual contact
• Mother-to-child transmission in pregnancy and at birth (perinatal)
• Parenteral (blood-to-blood)
• Horizontal transmission through close personal contact or sharing of infected items. This 
mode of transmission is seen mainly in early childhood.
The most predominant mode of Hbv transmission is perinatal. if a pregnant woman is an Hbv 
carrier and is also hepatitis b e antigen (HbeAg)-positive, her newborn baby has a 90% likelihood 
of being infected and becoming an Hbv carrier. of these, 25% will die in adult life from chronic 
liver disease or liver cancer. Although HbsAg, HbeAg and Hbv DnA have been detected in 
breast milk no differences in Hbv transmission rate according to feeding practices in early child-
hood have been demonstrated. 
other conditions that favor Hbv transmission include:
Kenyan situation 
in some parts of Kenya up to 12.5% of children under 4 years have been found to be HbsAg 
positive and by adolescence over 50% have some marker of Hbv infection, with 7 -10% being 
carriers of HbsAg.(13, 14, 15). results of different studies have varied depending on the geo-
graphic area and the diagnostic rnethod used. 
Greenfield et al (13,16) established that perinatal transmission is relatively unimportant in Kenya, 
as a result of low levels of circulating Hbv-DnA in the maternal plasma. They found 8% of 3000 
mothers to be HbsAg positive and only 4 ol,lt of 52 samples of HbsAg positive mothers were 
HbeAg positive and 32 were anti-Hbe positive. based on the above findings in conjunction with 
the: very low prevalence of anti-Hbc at 12 months it would seem that in Kenyan children, perina-
tal transmission does not play an important role and that Hbv transmission is mainly horizontal. 
PATHOGeNesIs AND PATHOLOGY
Hbv is not cytopathic, but it is the immune elimination of infected hepatocytes which results in 
the clinical symptoms and the histopathological changes of Hbv infection. both the cell mediat-
ed immunity (cMi) and humoral immune response play a role. 
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The cMi response which is modulated by interferons, results in lysis of infected hepatocytes, with 
the cytotoxic t cells directed against the nucleocapsid protein displayed on the surface of the he-
patocyte, playing a major role in this process. Humoral immune response is directed against the 
envelope proteins of Hbv (which include the Pres1, Pres2 and s gene-encoded region). 
CLINICAL PReseNTATION 
incubation period averages 75 days. The incubation period for infection acquired via transfusion 
of blood or blood products may be shorter. 
infection with Hbv results in massive replication of virus in the hepatocytes. The viruses are then 
released into the blood. replication of the virus in the liver, and the host immune responses to it, 
are responsible for the acute and chronic manifestation of the infection. Most infections go un-
recognized as symptoms may be mild or non specific. same patients develop an acute self limiting 
illness accompanied by jaundice and elevations of the liver enzymes. 
The likelihood of developing clinical hepatitis as a result of Hbv infection varies directly with 
age. in infancy and childhood, though fatal cases do occur, only 1 - 10% of acute infection are 
diagnosed clinically. While 33% of patients older than 30 years develop symptomatic disease 
(17). fulminant hepatitis is also commoner in older individuals. A fulminant course may be re-
lated to enhanced immune response with rapid clearing of virus and high titers of anti-Hbs and 
anti-Hbe. This may be associated with features suggesting immune complex disease manifested 
as fever, urticarial rash and arthralgia. 
HBV Carriers 
A carrier is a person whose serum is repeatedly HbsAg positive over a six month period or longer. 
10% of sufferers of Hbv infection will become chronic carriers of the virus, with the possible 
later development of chronic hepatitis, cirrhosis and hepatocellular carcinoma (Hcc). 
The chances of developing~HbsAg carrier state decreases with age. During infancy, it is as high 
as 90% in infants born to HbeAg positive mothers compared to 7.7% carrier state in persons 
infected after the age of 30 (17). 
Males are 6 times more likely to become carriers than females. Development of the carrier state 
seems to depend on the humoral and cMi response of the patient. When these are defective, 
viral replication continues with an increased likelihood of chronic carrier state. This is especially 
important in neonates, patients with malignancies and other immuno-compromised states. 
The carrier state therefore occurs more commonly in:
• males 
157
• those acquiring infection in childhood 
• those with immuno-deficiency states 
it is this chronic carrier state with its associated ijver damage that is of importance. it is the stage 
that immunization programmes are geared to eradicate. 
chronic hepatitis often occurs in carriers, with insidious progression to macronodular cirrhosis 
and eventual development of hepatocellular carcinoma. 
The factors that eventually cause malignant transformation are unknown but viral 
integration into the host genome and cessation of replication in the transformed cells has been 
shown in liver tumours. other incriminating evidence are:
• Hbv-DnA has been isolated in the genome of Hcc cells 
• Hcc in all parts of the world is associated with a higher HbsAg seropositivity than in age-sex 
matched controls 
• in taiwan a prospective study among chinese men revealed that the risk of Hcc among 
HbsAg carriers was approximately 100 times higher than among non-carriers(18) 
• Experimental studies with woodchucks (small forest animals found in n. America) who expe-
rience natural infections with viruses which are structurally very similar to Hbv, showed them 
to be at increased risk for developing Hcc. 
Complications of HBV infection
complications of Hbv infection include:
• acute hepatitis 
• chronic hepatitis 
• cirrhosis 
• vascular disease 
• glomerulonephritis
• primary hepatocellular carcinoma.
Though case fatality for acute Hbv infection is estimated at 1.5per 1000, studies have 
shown that the relative risk of dying among individuals with serologic markers are higher. When 
considering males younger than 40 years, feret et al in senegal found that those who were HbsAg 
positive were 3.5 times more likely to die than the controls. 
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The morbidity of Hbv though as yet unmeasured, probably has even a greater negative economic 
impact in developing countries due to decreased productivity J since chronic hepatitis, cirrhosis, 
and hepatic cellular carcinoma affect principally individuals from 15 to 59 years of age (8). beas-
ley et al (18) found that HbsAg carriers had a 280 times greater risk of developing primary ijver 
cancer than HbsAg negative individuals. in Asia, the cumulative risk of developing Hcc for 
HbsAg carriers over a 50 year period has been estimated to be 15% (19). 
Chronic Hepatitis 
chronic active hepatitis develops in about 25% of HbsAg carriers with eventual progression to 
cirrhosis or chronic liver failure, or hepatoma. 
A person with stabie chronic hepatitis may suffer relapse, marked by elevations in the serum trans-
aminase. relapse may be spontaneous, (in 10 - 15% of patients annuaHy), or due to super-added 
infection from delta virus, hepatitis A, non-A non-b(nAnb) or may follow antiviral therapy. 
During Hbv infection, the viral genome becomes an integral part of the patients genome, such 
that viral genes are transcribed along with those of the host. clones of these integrated cells farm 
the basis of malignant transformation. 
MANAGeMeNT
The management of Hbv infection will depend on whether it is acute or chronic. 
Acute Infection 
There is no known effective treatment and case management is geared towards supportive care. 
Chronic Hepatitis 
two types of chronic hepatitis are distinguished as treatment varies in these 2 categories:
• chronic Hepatitis in individuals who are HbeAg positive 
• chronic Hepatitis in those who are anti-HbeAg positive or HbeAg negative. 
Chronic Hepatitis with HBeAg Positivity 
Antiviral agents are administered to accelerate clearance of HbeAntiginaemia. These agents in-
clude adenine-arabinoside-monophosphate (Ara-AMP) and interferon. 
Chronic Hepatitis with anti - HBe Positive 
in asymptomatic persons or those with only mild symptoms, conservative measures are offered. 
if symptomatic, with grossly abnormalliver tests, and an active chronic 
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hepatitis on liver biopsy, then a short course of prednisolone (for about 8weeks) , the withdrawal 
of which is followed by a course of Ara-AMP or interferon has been shown to have good results. 
Co-Infection 
Coinfection or superinfection with HDV
co-infection or superinfection with delta virus has been associated with an increased morbidity 
and mortality from both acute and chronic Hbv infection. Hepatitis Delta virus (HDv) is a de-
fective virus that is only infectious in the presence of active Hbv infection. HDv infection occurs 
as either coinfection with Hbv or superinfection of an Hbv carrier. coinfection usually resolves. 
superinfection, however, causes frequently chronic HDv infection and chronic active hepatitis. 
both types of infections may cause fulminant hepatitis
Coinfection with HIV
• Hbv infection is associated with increased severity of liver disease in Hivinfected patients 
• in Hbv/Hiv-coinfected patients, necroinflammatory activity in the liver tends to be milder, 
but higher Hbv replication results in more severe liver fibrosis with increased risk for cirrhosis 
and a more rapid progression to end-stage liver disease 
• Patients coinfected with Hiv and Hbv, especially those with low cD4+ nadir counts, are at 
increased risk for liver-related mortality 
• Hiv appears to be a risk factor for reactivation of hepatitis b in patients who have developed 
hepatitis b surface antibodies, especially in patients with severe immunodeficiency
Super-infection with Hepatitis C
Acute Hcv infection in patients with chronic Hb infection may be associated with more severe 
symptoms during the acute phase.Patients with Hcv superinfection have higher cumulative rates 
of liver cirrhosis and hepatocellular carcinoma than acute Hbv superinfection or cHb. under-
lying Hbv infection is also an important factor determining the clinical course of acute Hcv 
infection. fulminant hepatic failure is significantly higher among those with underlying Hbv 
infection.
Super-infection with Hepatitis A
Acute Hepatitis A virus infection is severe and potentially fatal in patients with underlying chronic 
Hbv.
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CONTROL AND PReVeNTION
Methods of control include:
●	 Health education 
Health education aimed at change of behaviour patterns that favour spread of Hbv. blood is 
considered as an important vehicle for infection and thus its screening for Hbv markers is essen-
tial. sharing of razors and toothbrushes and the use of unsterilized needies and syringes should 
be avoided. it should be remembered that the primary source of infection is the acutely infected 
individual and the chronic carrier. 
●	 Immune serum Globulin (Hepatitis B immunoglobulin HBIG)
HbiG is human immune globulin prepared from pooled human plasma from persons with high 
titers of anti-Hbs. 
it is used primarily for prevention of perinatal transmission of Hbv in mothers who are HbeAg 
positive. 90% of HbeAg positive carrier mothers infect their babies while only 5% of HbeAg 
negative mothers infect their babies. to be effective it should be given within 48 hours of delivery. 
The dose of HbiG is 0.5mls, containing at least 300 iu and can be given concurrently with Hbv 
vaccine using different injection sites. it has been shown that concurrent use of vaccine and HbiG 
for infants born to mothers with high levels of circulating HbeAg can prevent the chronic carrier 
state in 85-95% of such infants, whereas use of vaccine alone can prevent the chronic carrier state 
in 70-90% of such infants  
Limitations of HbiG include high cast and short duration of prophylaxis. in newborns, anti-
bodies to HbsAg decline 2-3 months after HbiG therapy, leaving the infant at risk of infection. 
because of these reasons, many countries, for economic and logistic reasons would opt for Hbv 
vaccination alone. 
●	 Immunization 
no effective therapy has been found for treating the chronic Hbv carrier state.  change of some 
of the behaviour patterns associated with transmission are difficult to modify, therefore the main 
stay of control of this disease depends on prevention of transmission by immunization of popu-
lations at risk. 
What Levels are Protective? 
several studies have shown that anti-Hb titres greater than 1o iu/L are protective against the 
disease, though szmuness in his study found that after immunization, the vaccine efficacy was 
protective regardless of the antibody levels
161
Goal of HBV Immunization 
The goal of immunization is protection against Hbv carrier state with its consequent develop-
ment of liver disease and hepatocellular carcinoma. Hbv has been claimed to be the first an-
ti-cancer vaccination. 
rationale for immunization 
• The goal of vaccination is particularly to prevent the carrier state and hence avoid its sequelae. 
The risk of developing the carrier state is highest in infancy and early childhood and dropsrap-
idly with increasing age. The age at lowest risk of becoming a carrier is not known. 
• in same areas of Kenya up to 25% of the population have HbsAg, with 90% showing markers 
of previous or past infection. Most of these infections start early, though perinatal transmis-
sion is not important. 
• This set-up is ideal for justification of hepatitis vaccination during infancy. 
• if used in early infancy, it can reduce chronic carrier rates by over 75%. Hbv infection differs 
from other EPi-targeted diseases in that the majority of the related morbidity and mor1al-
ityoccurs during the adult period following relatively asymptomatic perinatal or childhood 
infection. 
• The importance of Hbv is stressed by the fact that more than 40% of persistently infected 
persons who survive to aduit life will die as a consequence of their infection. 
• Mortality from Hbv must thus be viewed with regard to effect ot deaths ot an economically 
productive adult. A moriality rate ot 0.5% per year from Hbv related ijver disease in adult 
carrier males has been observed in hyper-endermic area. since Hbv carriage rate in hyperen-
demic areas is about 10-15%, death due to liver disease would therefore account for 3% of 
the deaths. 
• incorporating Hbv vaccine into the existing EPi programme would be economically teasi-
ble since logistical support, cold-chain provisions, and the vaccination schedule would allow 
administration ot other antigens at little additional cost for delivery. With reductions ot oost 
ot Hbv vaccine, the cost ot preventing death from the Hbv related Hcc and cirrhosis ap-
proaches that reported for the EPi diseases. 
• since EPI vaccination schedules differ from country to country, there should be some flexibil-
ity in dosage schedules for Hbv vaccine in order to allow for integration of this vaccine with 
the other EPi antigens. 
• in the high risk adult population Hbv vaccine protects from development of acute infection 
which though more severe than in childhood, has lower risks of progressing to a chronic car-
rier state. 
VACCINe DeVeLOPMeNT AND Use 
Epidemiologic studies of natural hepatitis b infection showed that the development of anti-Hbs 
conferred protection against subsequent infection. consequently an effort was made to produce 
a vaccine using purified HbsAg as the immunogen. two generations of Hb vaccine have been 
developed namely: 
• first generation plasma derived vaccine 
• second generation Hb vaccine
First Generation Vaccines
Development of a Hb vaccine was initially hampered by the inability to grow Hbv in cell culture, 
but the pioneering work of Krugman et al established the feasibility of producing a vaccine from 
serum containing Hbv Ag. 
first generation plasma derived vaccines were developed by separating these particles from the 
complete virus in the blood ot chronic carriers, and were licensed for use early in the 1980’s. 
usually, during Hbv infection or even in the carrier state, apart from the whole virus particle 
(Dane particle) there are several tubular and spherical particles about 22nm diameter representing 
surplus viral coat protein (HbsAg). These particles are antigenic and stimulate the production of 
anti-Hbs. Anti-Hbs is believed to be the protective anti body and the aim of vaccination is to 
stimulate production of anti-Hbs. 
to render this vaccine safe, it undergoes several purification processes. major purification processes. 
• heat inactivation 
• formalin
• hyperosmolar urea
Each of these methods can destroy whole Hbv as well as any other infective agent currently iden-
tified (including Hiv). 
Plasma from the donor is also screened for Hiv antibodies and reverse transcriptase activity (to 
detect retroviruses). 
second Generation HB Vaccines 
Three approaches have been used to produce second generation Hb vaccines:
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• Recombinant DNA Technology 
Molecular cloning and sequencing of the Hbv genome and the identification and 
cloning of the s-gene which codes for the major viral surface polypeptide led to the produc-
tion of HbsAg by genetic engineering. 
currently yeast derived Hb vaccines are in use and several studies have shown them to be safe, 
highly immunogenic and effective. 
• Synthetic Peptides 
Peptides of 8 to 12 amino acids following the amino acid sequences of hydrophilic regions 
of the surface antigens that are thought to be the specific antigenic sites have been produced. 
The main disadvantage of this type of vaccine has been it’s low immunogenicity. research is 
currently focused on enhancing the response by attachment of the peptide to large carrier 
molecules. 
• HBsAg - Producing Hepatoma Cell Lines 
HbsAg particles produced by hepatoma ceillines are identical to those detected in 
plasma of HbsAg carriers. The main concern about the use of vaccine derived in this way has 
been the safety of using a vaccine that might contain oncogenes, especially since other “safer” 
Hbv vaccines are available. 
Vaccine Dosage
The vaccine dosage depends on the type of vaccine being used. Manufacturers process and for-
mulate their vaccines differently, preventing meaningful comparison of dosages of vaccine from 
different sources. 
According to data submitted to WHo/EPi/Geneva by manufacturers in 1990, an efficacious 
paediatric dose may include anywhere from 1.5 to 10.0 ug ot active material, depending on the 
manufacturing process. 
Vaccine Storage and Handling 
Most Hbv vaccines are moderately stable at room temperature but appear to be stabie for many 
years at 2 to 8 degrees c. The upper limit of storage life has not yet been defined and can be 
expected to vary among different manufacturers. inactivation of the vaccine occurs at highc am-
bient temperature and by freezing. The Kenya Expanded Programme on immunization’s recom-
mendation is 0 to +80 
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As with other adjuvanated vaccines such as DPt, freezing results in vaccine - adjuvant dissocia-
tion. freezing does not result in any visible changes in the vaccine, thus emphasizing the precau-
tion to avoid freezing and to include freeze indicators during shipment and storage. Hb vaccine 
should be handled the same way as DPt vaccine. 
The prospect of using a quadruple vaccine (DPt -Hb) holds great promise for facilitating the 
introduction ot Hb vaccination. it would obviate the need for a great deal. more cold chain and 
storage space as well as for more needles and syringes. 
Compatibility with other Vaccines
studies moniforing post-vaccination anti body titers have shown that Hb vaccine can be given 
with bcG, diphtheria, tetanus, pertussis, polio,. measles and yellow fever vaccination, with no 
reduction in immune response to any of the vaccines (28,29). 
A quadruple vaccine of DPt - Hb is being planned. All 4 immunizing agents are proteins which 
are adjuvanated and handled in a similar fashion. 
Indications for Vaccination 
The hepatitis b vaccine is recommended specifically for all infants and children. it is also recom-
mended that adults in high-risk groups be vaccinated. 
The following list is a general guide for vaccination, but since every person is at some risk for 
infection, these guidelines should be individualized for each situation. 
• All infants at birth and all children up to 18 years. 
• Health care professionals and emergency personnel. 
• sexually active teens and adults 
• Men who have sex with men. 
• sex partners or close family/household members living with an infected person. 
• Patients with kidney disease or undergoing dialysis. 
• residents and staff of correctional facilities and group homes. 
• Any person who may fall into a high risk group due to occupation or lifestyle choices. 
Age at Vaccination
The epidemiology of the carrier state is the primary determinant of the age at first doge. in Kenya, 
as in other parts of sub-saharan Africa, transmission is primarily horizontal rather than vertical or 
perinatal. While early vaccination is strongly recommended to minimize the time period during 
which there is risk of acquiring infection, it is not essential that the first do se be given immedi-
ately after birth. Therefore, vaccination can be given at birth, or soon after birth. 
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for practical purposes it could be given as three doses, 4 weeks apart concurrently with DPt 
starting at the age 6 weeks. reasons for giving it at this time are:
• hospital deliveries account for less than a half of all deliveries in developing countries, there-
fore not all babies will be seen at birth. in Kenya, only about 30% of all deliveries are conduct-
ed in hospitals, therefore this would not be an opportune time.
• giving Hb vaccine at birth may meet with same obstacles, as mothers may not like their babies 
receiving 2 injections (bcG is normally given at birth in Kenya) 
• it would be logistically simplier and more cost effective to incorporate Hb vaccine into the 
existing KEPi immunization schedule if it was given together with the DPt. This would also 
improve compliance as it avoids increasing the number of hospital visits 
• with the development of the quadruple vaccine (DPt,Hb) this would mean administering 
one injection instead of two. 
Recommended Route and site 
The recommended route of administration for HB vaccine is intramuscular. 
Though the intradermal route would be cheaper in terms of using a lower dosage, it is technically 
more difficult to administer an intradermal injection in infants. ff such an injection is inadvertently 
given subcutaneously or intramuscularly, then it would be ineffective and leave the child un-
protected. 
for neonates the recommended site is the anterior aspect of the thigh. in adults it is the deltoid 
region (gluteal region produces an inferior immune response - probably because of thickness of 
fatty layer, the injection may not be truly intramuscular). 
Duration of Protection 
following the third and last dose in the Hbv immunization series, anti-Hbs titres decline after 
about 5-6 years(7). There is individual variation in the rate of decline. in infants and children 
there have not been long enough follow-up studies to determine when to give booster doses. 
studies have shown that even when anti body levels become undetectable, individuals seem to 
remain protected against clinically significant disease (HbsAg carriage or liver inflammation) , 
provided that the initial anti body response was effective. boostering to maintain anti-Hbs levels 
above 1 ou/mi were found to be unnecessary in endemic areas. beasley, found that in taiwan-
ese children the initial fair in anti body titers does not continue probably because of “natural 
boosters”(30). booster doses may therefore be unnecessary to maintain effective immunity and to 
prevent new carriers. 
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The vaccine has not been used long enough to establish documented evidence in prevention of 
chronic hepatitis, cirrhosis or Hcc. However the ability of the vaccine to reduce or prevent Hbv 
carrier state - the forerunner of Hbv induced chronic hepatitis, more than justifies promotion of 
immunization programme’s. 
Immunogenicity
HbsAg antigenicity is enhanced by absorption to an alum adjuvant. 
Factors influencing immunogenicity 
immunization in early childhood is more effective than in adults and immunogenicity in neo-
nates is excellent irrespective of Hbv marker status of the mother. Maternal antibodies or even 
HbiG administration does not inhibit anti body production after vaccination. freezing inacti-
vates the vaccine because it causes vaccine-adjuvant dissociation. 
Non Responders 
Although the majority of persons vaccinated against hepatitis b successfully respond to vaccina-
tion, an estimated 5-15% of persons may not respond. it is possible that a person who does not 
respond to the vaccine may already be infected with hepatitis b. Therefore, testing for the presence 
of the virus (HbsAg) is recommended before diagnosing a person as a “vaccine non-responder”.
• non-responders who are HbsAg-negative should be considered susceptible to Hbv infection 
and should be counselled regarding precautions to prevent Hbv infection and the need to 
obtain HbiG prophylaxis for any known exposure to HbsAg-positive blood. 
• non-responders who prove to be HbsAg-positive should be counselled regarding how to pre-
vent Hbv transmission to others and regarding the need for medical evaluation. 
repeated immunizations result in seroconversion in some of the initial non-responders. This ef-
fect is enhanced if larger doses are used. 
Efficacy of Vaccine 
The complete vaccine series induces protective antibody levels in more than 95% of infants, chil-
dren and young adults. After 40 years, protection level drops below 90%; by 60 years protective 
antibody levels are achieved in only 65-75% of vaccines. The duration of protection based on 
current evidence is life long
Side Effects 
side effects are few and are local and transient. They include pain and swelling at the injection 
site. fever and flu-like symptoms have been reported in a few cases. These side effects are mainly 
due to the adjuvant (alum) used in the vaccine. 
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Acceptance and tolerance have been shown by widespread use of plasma derived vaccine in Euro-
pean health workers and Asian EPi Programmes. Among 8 million doses of Pasteurs vaccine no 
cases of AiDs, Hbv, nAnb or autoimmune disease has been associated with the vaccine. Anxi-
eties have been expressed about safety of plasma derived vaccine and AiDs. However follow up of 
male homosexuals and medical staff vaccinated in us found no evidence to implicate the vaccine 
in the transmission of AiDs. This is not surprising because the processing of the plasma-derived 
vaccine does not permit survival of infectious agents. 
Contraindications
There are no contraindicators to giving HB vaccine. it can be administered to patients incubating 
Hbv, subjects positive for HbsAg, anti-Hbc or anti-Hbs and immunocompromised individuals. 
Cost Effectiveness of Vaccine 
When reviewing cost effectiveness of Hb vaccine it should not be looked at only as preventing 
the acute infection but rather at the sequelae of the acute infection i.e cirrhosis and hepatocellular 
carcinoma which seem to affect males more, and afflicts at the prime of an individuals life. 
The economic impact of curtailing such productive resource persons is enormous especially in 
developing countries, leave alone the economic resources required for provision of health care to 
such patients. 
Where prevalence of Hbv carrier is low, targeted immunization of high risk individuals is 
appropriate. This, however depends upon the cost of the vaccine and of screening tools. 
in areas of high endemicity or areas where acquisition of infection is in early childhood, the uni-
versal vaccination of all children in the first 6 months of life is reccomended. 
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